Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779108 | 0.82 | LTA4H (0.55) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL11009131 | 0.79 | TSHR (0.52) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL14638504 | 0.77 | TSHR (0.44) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6313882 | 0.76 | APP (0.53) | LMNACYP1A2CYP2C19MAOBRAB9A | |
| SCHEMBL24844977 | 0.75 | APP (0.50) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL17010218 | 0.75 | MAOB (0.55) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL17012038 | 0.75 | CYP1A2 (0.46) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL1735498 | 0.75 | MAOB (0.50) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL28776503 | 0.75 | PIN1 (0.49) | TSHRLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL30046416 | 0.74 | KDM4E (0.48) | CYP1A2CYP2C19L3MBTL1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153654-B | Method for producing isocyanuric acid derivative having 1 hydrocarbon group | 日产化学株式会社 | 2022-11-11 | — | — | CN | disclosed |
| CN-107011168-B | Synthesis intermediates of cytosines and synthesis intermediates of thionucleosides | 富士胶片株式会社 | 2020-06-09 | — | — | CN | disclosed |
| CN-109153654-A | The manufacturing method of isocyanuric acid derivative with 1 alkyl | 日产化学株式会社 | 2019-01-04 | — | — | CN | disclosed |
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2014025993-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-7825096-B2 | O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2134715-A2 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109735-A2 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20070213279-A1 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS AND BETA-GLUCURONIDASE CLEAVABLE PRODRUGS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE | 2007-09-13 | — | — | US | disclosed |
| US-6172070-B1 | IN POLYOXYETHYLENE GLYCOL CARRIER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-01-09 | — | — | US | disclosed |
| US-6096724-A | O(6)-ALKYLGUANINE-DNA ALKYLTRANSFERASE (ATASE) ENZYME INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5958932-A | ANTITUMOR AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-28 | — | — | US | disclosed |
| US-5929046-A | Pyrimidine and purine derivatives and their use in treating tumour cells | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5916894-A | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| US-5753668-A | Substituted benzyloxypyrimidines and their inactivation of O6 -alkylguanine-DNA alkyltransferase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5525606-A | CHEMOTHERAPEUTIC ANTITUMOR AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, GRIN2A | TSHR 3062/4885LMNA 4815/4885CYP1A2 2331/4885 |
| US-20070213279-A1 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS AND BETA-GLUCURONIDASE CLEAVABLE PRODRUGS | UNG, OGG1, MPG | TSHR 2852/4885LMNA 1100/4885CYP1A2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.